Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Fresenius v. Baxter: BIO files Amicus Brief in Federal Circuit

shutterstock_1092009

The Biotechnology Industry Organization filed an amicus brief at the Federal Circuit in the case of Fresenius v. Baxter: BIO is concerned that the panel decision could have a number of unintended consequences, such as incentivizing defendants (or declaratory judgment plaintiffs) to employ dilatory tactics in the federal courts while re-arguing already-decided issues under claim construction more favorable to the patent challenger and lower burden-of-proof standards in the PTO.  Courts and parties may be forced Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Bayh-Dole and Technology Transfer Continue to Deliver

87881842

The Association of University Technology Managers released the 2012 AUTM U.S. Licensing Activity Survey Highlights which provides data on respondents from “161 universities, 32 hospitals and research institutes, and one third-party technology investment firm” (a response rate of 65%).  Here are some of the highlights: Start-Ups and Products: • 705 startup companies formed (+5.1% [over last year]), 554 of which had their primary place of business in the licensing institution’s home state (+13.8% [over last Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Patent Docs Highlights the BIO IPDx Symposium

shutterstock_10020697

Patent Docs recently highlighted McDonnell Boehnen Hulbert & Berghoff’s (MBHB) panel at BIO’s IP and Diagnostics Symposium (IPDx).  Moderated by Donald Zuhn at MBHB, panelists from MBHB, Roche Diagnostics, and the USPTO discussed the impact of the Myriad decision on obtaining patent protection for genetic diagnostics.  The panel concluded the following: “While there was agreement that the Myriad holding is not limited to human DNA, there was spirited disagreement regarding its long-term impact on patents claiming naturally Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO IP & Diagnostics Symposium

Final IPDX logo

BIO’s IP & Diagnostics Symposium (BIO IPDX) will review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. The program will review IP issues for both diagnostics generally and companion diagnostics. The program will also explore some of the potential regulatory dimensions. BIO aims to use this event to inform industry and government alike on how to move the science forward in the current climate. Where & Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Joins Alliance for Fair Trade with India

shutterstock_26191726

BIO recently joined the Alliance for Fair Trade with India along with the U.S. Chamber of Commerce, the National Association of Manufacturers, Solar Energy Industries Association, and others. The new Alliance website states: Over the last year, policymakers and courts in India have engaged in a persistent pattern of discrimination that is hurting a wide range of manufacturing and services industries and jobs in the United States. India has recently mandated domestic content rules that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,